{"name":"Cancer Prevention Pharmaceuticals, Inc.","slug":"cancer-prevention-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Eflornithine plus Sulindac","genericName":"Eflornithine plus Sulindac","slug":"eflornithine-plus-sulindac","indication":"Colorectal cancer prevention in high-risk populations","status":"phase_3"}]}],"pipeline":[{"name":"Eflornithine plus Sulindac","genericName":"Eflornithine plus Sulindac","slug":"eflornithine-plus-sulindac","phase":"phase_3","mechanism":"Eflornithine inhibits polyamine synthesis while sulindac acts as a non-selective NSAID to reduce inflammation and promote apoptosis, together targeting colorectal cancer prevention.","indications":["Colorectal cancer prevention in high-risk populations"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOeER1b3dhdVdpNVNUV1ExSVkxempaNkI4OGNhbXpDUjBOVkJqS1ZOd1NjS0YxLUlmV0pMdnVLTHFDQWVERGVrZHZneFFZYlFjVEFFYW5Sd1FBeXhsdE4tRzdkVjVZcXJQWXNuVEVCcFotYlBWWUJjZjZLWHdQSi1IMzJ1WURLYXdI?oc=5","date":"2026-02-16","type":"pipeline","source":"Pharmaceutical Commerce","summary":"Pharma Pulse: The $1.5 Billion Weight Management Gamble and a Cancer Prevention Breakthrough - Pharmaceutical Commerce","headline":"Pharma Pulse: The $1.5 Billion Weight Management Gamble and a Cancer Prevention Breakthrough","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOd0dUbG1SWFZybUZ4V1BxRmFLS1ZXSWR3RVhRT1pZSG1QOWRrSC0zQ1AwWnFXNkw1T0h1M3paVTljSzE5a1pQak9YUWtySVBFUElfY0VKSkxyb1BJNHhuT1VCX2hMeGc2VlpDbW4wbXVtbUNTTGd4aHdHUmdzSkN6T0pVOFljclhlYjF1NTdOZThRVTZCSVow?oc=5","date":"2026-02-13","type":"pipeline","source":"Pharmacy Times","summary":"Aspirin’s Evolving Role in Cancer Prevention and Outcomes - Pharmacy Times","headline":"Aspirin’s Evolving Role in Cancer Prevention and Outcomes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOcmh3SnJxbUc0OTk5VGc2S2xNVHFoYm9pWll0N1hSRFA3WG1CbUFLeVJVV3dhc0lkZExvNkFEN082eDZ4TUhtNks4MEtnNjF3UlJkT3RPZWZGdERkTC1YSWxuMTNLcGVtelZ5a2ptNnBLMUs5a0dvaXMxVllXRExudkg2ajhzOHY5QU9kenBnZC1mbHpPQVpvaU96VUlYcXV6X3FyelJJLXV1c0ZVb0NGcg?oc=5","date":"2026-01-30","type":"regulatory","source":"Pharmacy Times","summary":"Jeff Goad - Changes to HPV Vaccine Guidance Could Be Problematic for Cancer Prevention - Pharmacy Times","headline":"Jeff Goad - Changes to HPV Vaccine Guidance Could Be Problematic for Cancer Prevention","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNVV9hOHRickNKeDFicWI3elZoMjh0cXQ0NTRMa0V0V1JmRTNvVE05WGZPbXMtck5RYzFibnFpd1BVZ3lJdFRXRi1qYkJnaGxPTEFleHltdFAzbWtGYjBxaGcySkFJeTVnY2ZkWEVrOHF3QTBNWlNPaks5RG50RjVtSldKQmZCT3JCcUZLMEZCMVdCUmc5OUE?oc=5","date":"2025-12-01","type":"trial","source":"Yahoo Finance","summary":"Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 - Yahoo Finance","headline":"Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Ad","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNZm9SV0pZNTI1My1KLS1tMVNnNElpT2J2S2IyLVE2akpYOEZrakJaaDdxZmIzRGs3R2JOd3dPX0NxSzNyNzNiVXgtb3BhQjg0Q3cyZnFRMEIxZXlKUHZhZ0hDYUt1MkZMSUVlSDVZV3I1ZUtDdXlhdFFJdTlQMXFXWjBBTnA5ZnBzNlk4eVlfRTVqQ2p1UXc?oc=5","date":"2025-11-14","type":"deal","source":"statnews.com","summary":"Merck to buy Cidara, maker of a flu prevention drug, for $9.2B - statnews.com","headline":"Merck to buy Cidara, maker of a flu prevention drug, for $9.2B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOcm1McnpwdXpIeENNSDlNVHlwNDFzNHBndWhzVXoyaDFacXloLXpjV2pqbTUwckJ2T18wZzN3ZFhWRmZvaXh1N1pLc2F0NGJablRHVlFTdWhWX3hFNld2N1Roa3h4aUl2MWptYjltRFlYWjZXMjZpTmdnVi04bjNXNHdkSzRvME9qbVFfd01va3ZKQXpXWTRQa1RUV0tVYVlXaXZrM2JoT2FQZERPTjlwQnVTZDNmNnRGZFl5cUlaUTRSVXpMdllkVHZ6aUFnZUhoQU9ocUc0cw?oc=5","date":"2025-10-30","type":"regulatory","source":"Reuters","summary":"Gilead posts higher profit on demand for HIV drugs, but overall sales dip - Reuters","headline":"Gilead posts higher profit on demand for HIV drugs, but overall sales dip","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNcnZxZDQ5RGh0aV8yYUhjcF9ReVhmSzhLcDFOWXAwYWNpZXVCZXZ4bEpJUHJBTnI5Z2lYbk5RQ3FsMnJJTHJ4UnJ0aGlITG5wMFY2bE5qQkNQVjRMVUh2UlJQSFJ2Z3hvSmVIcTBNbVMxcXI5SVdFNktGc0otS3BZX05XWlp2ejJvemt0WWJQNERmeDV6clBTa3dSMFJoYWcxSWRudzlxckUxUDJNZ3JjZDBaOWNadFhydWpRU1piOUxXNC1JODhDRXFKOWVmSnM?oc=5","date":"2025-04-24","type":"earnings","source":"Reuters","summary":"Gilead posts profit, says HIV prevention drug on track for mid-June - Reuters","headline":"Gilead posts profit, says HIV prevention drug on track for mid-June","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE0wWmFVcWplRWJpSHhNRUVydlhkYV9QRThYOUZNcU9lejJUVFlTRjlualBVOXprMGhWRWxDcHRIUFhQbWk2aXdvandhZDVmOTZjcXVUSUY5bUQycDJuckdvY21n?oc=5","date":"2025-04-22","type":"pipeline","source":"The Pharma Letter","summary":"Tempest Therapeutics - The Pharma Letter","headline":"Tempest Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE10emFQUDFwX3BYOWk2NnFxZnpybWxsamJUeHQ3NmRKYi1zYkZ2RFZxMEd5NmsyTHY5bU1PYXFWdjBPRTJQbExiVldUSmVBc2RzZDUwZW1lemRlVXlKQ3d1LVZjOER1V1JnZmZvZ3lrUnRxeWtZ?oc=5","date":"2025-03-23","type":"pipeline","source":"British Pharmacological Society | Journals","summary":"Natural products and cancer: From drug discovery to prevention and therapy - British Pharmacological Society | Journals","headline":"Natural products and cancer: From drug discovery to prevention and therapy - British Pharmacological Society | Journals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFAwWHFEYnJsTnVyNXlHWFF0SG9GWk9wTVcyMGk4VXg0UHVtVUYzWHNjaUJGUko3bFZ4U1BHMUN3dERublNyZDFPSzBtZkxmLWVKRXNqX3k2NWZJY1RfZVd3VmtRUUhrcUxhNW5kR0FocHRmV0ZwWVMyVlBua0k4U3M?oc=5","date":"2023-04-12","type":"pipeline","source":"Pharmaceutical Technology","summary":"Panbela obtains rights for Flynpovi to treat FAP - Pharmaceutical Technology","headline":"Panbela obtains rights for Flynpovi to treat FAP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOUUxraGRvbHV5bFc0SXhLbGJzdVhCVzVXQ3ZVd09oRVE3ZWQ0MFZvbXVlRldtTWVzSlM0U3JrcmVIS0dULXktaFU3N19QdzBnNHdQM3lKcUs4NVVpekNUMU1SMnc3TThLWlgwbEV0UEEzUnY2alJIcXk5Q18zRFJySkJZLTRUNTlnN0Z4c0RHUlMyUQ?oc=5","date":"2022-02-24","type":"deal","source":"Arizona Daily Star","summary":"Tucson cancer-drug startup acquired by Minneapolis firm - Arizona Daily Star","headline":"Tucson cancer-drug startup acquired by Minneapolis firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxQbkE5bERZUEszNTRlNms5eXNyZnJIWVByUWFzcFo5el9nbmJIdUN1bnl4QWNIcXZFczY0LWdpTXhFWU5QcE1EVDBSM0hmUFdjR3NIRGwyMzRabVF6b1hsYmlKVmhGXzFsSTVmelltUzNIb0g2TFZKT1lvY25HSklwM3FtQTdYRzVudnFtbXJUbjJiVzhXWVgwV2tkY3p0RkE1TEZjNC03eW95YXFJZGZ6eEZ4UXBNQWdmX0ppQ0JVa1BfMmJXeTRMc3BwZ1d6SkEtYjFvMEQ5Nkx6UVJxVXVrai1FOXJmSjJWd0RYeS1YajRtV0FodTNfcHhrUi1EVVlQVncwREIwbEhhWU11Zmtod0staWxIX19xbFpxTkRkUDNsME5tWWdCU09TR3VpVmRSek5QQ3ViNjVyaF9DVi1JNG5B?oc=5","date":"2019-05-07","type":"trial","source":"PR Newswire","summary":"Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients with Familial Adenomatous Polyposis - PR Newswire","headline":"Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac ","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}